Literature DB >> 24567186

Functional analysis of three novel cell lines derived from human papillary thyroid carcinomas with three different clinical courses.

Mayumi Ishikawa1, Toshiaki Tachibana, Hisashi Hashimoto, Junko Toyomura, Toshihide Ito, Kumiko Tsuboi, Kazutoshi Shibuya, Takahisa Hirose, Shiro Minami, Gen Yoshino.   

Abstract

Papillary thyroid carcinoma (PTC) is the most frequent thyroid carcinoma. PTC cell lines have been of considerable value in studying aspects of thyroid cancer, such as gene expression, cell proliferation, and differentiation. Here we report three novel PTC lines established from three patients with different backgrounds. Case 1 was a 38-year-old woman with PTC in the right thyroid lobe, with no metastasis. The cell line was established from the resection sample and named D-PTC. The cell line consisted of epithelial cells with few lysosomes and showed a pavement structure and follicular formation at confluency. There was a little pilling up. The secretion of free thyroxin (fT4) and thyroglobulin (Tg) was increased by TSH, or GH and IGF-I treatment. Case 2 was a 22-year-old woman with PTC initially in the right thyroid lobe, but 4 years after the right lobe resection, PTC metastasis was observed in left lobe. The cell line was established from a sample of the second resection and named UD-PTC. This cell line consisted of small epithelial cells with evident lysosomes and exhibited floating cell clusters. The secretion of fT4 and Tg was slightly increased by TSH, or GH and IGF-I treatment. Case 3 was an 85-year-old man with PTC and with acromegaly. Metastasis was observed at cervical lymph nodes. The cell line was derived from the metastasis region and named A-PTC. This cell line consisted of small epithelial cells and many lysosomes. The cells frequently showed pilling up. The secretion of fT4 and Tg was significantly increased by GH and IGF-I treatment. We have established three PTC cell lines with substantial variation in their phenotype. The cell lines may be useful for thyroid cancer research.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24567186     DOI: 10.1007/s13577-014-0088-9

Source DB:  PubMed          Journal:  Hum Cell        ISSN: 0914-7470            Impact factor:   4.174


  33 in total

1.  Establishment of a non-tumorigenic papillary thyroid cell line (FB-2) carrying the RET/PTC1 rearrangement.

Authors:  Fulvio Basolo; Riccardo Giannini; Antonio Toniolo; Rosario Casalone; Marina Nikiforova; Furio Pacini; Rossella Elisei; Paolo Miccoli; Piero Berti; Pinuccia Faviana; Lisa Fiore; Carmen Monaco; Giovanna Maria Pierantoni; Monica Fedele; Yuri E Nikiforov; Massimo Santoro; Alfredo Fusco
Journal:  Int J Cancer       Date:  2002-02-10       Impact factor: 7.396

2.  Growth inhibition of new human thyroid carcinoma cell lines by activation of adenylate cyclase through the beta-adrenergic receptor.

Authors:  K Ohta; X P Pang; L Berg; J M Hershman
Journal:  J Clin Endocrinol Metab       Date:  1997-08       Impact factor: 5.958

Review 3.  Thyroid cancer.

Authors:  O Gimm
Journal:  Cancer Lett       Date:  2001-02-26       Impact factor: 8.679

4.  Establishment of xenografts and cell lines from well-differentiated human thyroid carcinoma.

Authors:  J D Lin; T C Chao; H F Weng; H S Huang; Y S Ho
Journal:  J Surg Oncol       Date:  1996-10       Impact factor: 3.454

5.  Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors.

Authors:  Kazutoshi Takahashi; Shinya Yamanaka
Journal:  Cell       Date:  2006-08-10       Impact factor: 41.582

6.  Establishment and characterization of a human papillary thyroid carcinoma cell line with oxyphilic differentiation (ONCO-DG 1).

Authors:  D Grimm; F Hofstädter; J Bauer; T Spruss; P Steinbach; G Bernhardt; R Menze
Journal:  Virchows Arch B Cell Pathol Incl Mol Pathol       Date:  1992

7.  The results of various modalities of treatment of well differentiated thyroid carcinomas: a retrospective review of 1599 patients.

Authors:  N A Samaan; P N Schultz; R C Hickey; H Goepfert; T P Haynie; D A Johnston; N G Ordonez
Journal:  J Clin Endocrinol Metab       Date:  1992-09       Impact factor: 5.958

8.  Multiple pluripotent stem cell markers in human anaplastic thyroid cancer: the putative upstream role of SOX2.

Authors:  Valeria Carina; Giovanni Zito; Giuseppe Pizzolanti; Pierina Richiusa; Angela Criscimanna; Vito Rodolico; Laura Tomasello; Maria Pitrone; Walter Arancio; Carla Giordano
Journal:  Thyroid       Date:  2013-06-21       Impact factor: 6.568

9.  Establishment of a highly differentiated thyroid cancer cell line of Hürthle cell origin.

Authors:  A Zielke; S Tezelman; G H Jossart; M Wong; A E Siperstein; Q Y Duh; O H Clark
Journal:  Thyroid       Date:  1998-06       Impact factor: 6.568

10.  Oncofoetal fibronectin--a tumour-specific marker in detecting minimal residual disease in differentiated thyroid carcinoma.

Authors:  E Hesse; P B Musholt; E Potter; T Petrich; M Wehmeier; R von Wasielewski; R Lichtinghagen; T J Musholt
Journal:  Br J Cancer       Date:  2005-09-05       Impact factor: 7.640

View more
  1 in total

1.  Thyroid-related hormones as potential markers of hypoxia/ischemia.

Authors:  Naoto Tani; Mayumi Ishikawa; Miho Watanabe; Tomoya Ikeda; Takaki Ishikawa
Journal:  Hum Cell       Date:  2020-03-07       Impact factor: 4.174

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.